Security Reports > Flexion Therapeutics

Flexion Therapeutics
Data Breaches, Cyber Attacks and Security Report

https://flexiontherapeutics.com  ᛫ 
Last updated August 7, 2020

Flexion Therapeutics Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Flexion Therapeutics is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Flexion Therapeutics

Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".


Data Breaches and Security News


Security Report for Flexion Therapeutics

Want a security rating for your organization?

This report shows a preliminary security rating for Flexion Therapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Flexion Therapeutics's security performance with other companies